Cartalax vs Thymalin
The distinction that mattersSame Russian research tradition, and often sold together, but a different kind of thing. Thymalin is an undefined bovine thymus extract registered as a medicine in Russia; Cartalax is a single defined tripeptide that is not a registered medicine anywhere. The cartilage equivalent of Thymalin is the animal cartilage extract this peptide was derived from, which is also not the same substance.
These are not equivalent in evidence Thymalin is rated 2/5 and Cartalax is rated 1/5 — a gap of 1 level on our scale. Similar marketing does not mean similar proof.
| Cartalax Research Use Only | Thymalin Limited Approval | |
|---|---|---|
| Evidence rating |
1/5 Minimal
Evidence rating 1 out of 5: Minimal
|
2/5 Limited
Evidence rating 2 out of 5: Limited
|
| Regulatory status | Not an approved medicine anywhere. In Russia it is sold as a capsule food supplement rather than as a registered drug; elsewhere it moves under research-use-only labelling. No registered human trial exists as of September 2026. | Registered in Russia as an immunomodulator. Not approved in the US, EU or UK. |
| Category | Healing & Tissue Repair | Immune & Anti-inflammatory |
| Drug class | Synthetic tripeptide Ala-Glu-Asp, one of the Khavinson short peptide bioregulators, designed from the composition of an animal cartilage polypeptide extract | Polypeptide complex extracted from calf thymus — a mixture, not a single molecule |
| Route | Marketed in Russia as an oral capsule and on the grey market as a lyophilised powder for injection; neither route has been studied in a person. | Intramuscular |
| Half-life | Never measured. No pharmacokinetic study of this sequence has been published in any species, so nothing is known about how long it persists or where it goes. | Not applicable — heterogeneous mixture |
| Sequence length | 3 residues | Mixture — no single sequence |
| Molecular weight | 333.3 Da | — |
| Studied in | Cell culture almost exclusively: human mesenchymal stem cells and chondrocytes in replicative-ageing models, human and rat skin fibroblasts, and human periodontal ligament stem cells. One rat study of cisplatin kidney injury included it among several peptides. No human study of any design has been published or registered. | Russian clinical studies in immunodeficiency and post-surgical infection; a long-term gerontology cohort study reporting mortality reduction in elderly participants. |
| Who should avoid it |
|
|
| Legal status | Cartalax has no marketing authorisation in the United States, the European Union or the United Kingdom, and is not a licensed medicine in any of them. It is not a controlled substance. In Russia it is marketed as a capsule food supplement rather than as a registered medicine, and the originating group's own review of this peptide family flags only one member as a medicinal product, which is not this one. There is no FDA substance-registry record for it at all, while its close relative Epitalon has one. It is not named on the WADA Prohibited List, but its clause for agents with no approval from any health authority reaches it. | Registered in Russia; unapproved elsewhere. |
Benefits — Cartalax
- Chondrogenic markers in ageing human stem cells
In human mesenchymal stem cells taken through replicative ageing, the peptide was reported to raise gene expression and protein synthesis of SOX9, aggrecan, type II collagen and COMP. These are the markers a cell moving toward a cartilage phenotype should show, measured in culture rather than in cartilage.
- Senescence markers normalised in cultured chondrocytes
In a model of the senescence-associated secretory phenotype of chondrocytes, it was reported to reduce p16, p21, p53, tumour necrosis factor alpha and interleukin-1 alpha and to restore sirtuin-1. The readouts are immunostains of cells in a dish, not joint tissue or joint function.
- Sirtuin and collagen response in ageing fibroblasts
In human skin fibroblasts driven into replicative ageing, it raised sirtuin-1, sirtuin-6 and collagen I staining, in a comparison against a second short peptide that moved inflammatory markers instead. It is the most direct evidence that the sequence does something to a human cell.
- One whole-animal signal, in kidneys rather than joints
In rats with cisplatin-induced acute renal failure it reduced urinary protein and electrolyte excretion, though a different short peptide in the same experiment carried the protective effect. It is the only in-vivo result of note, and it has nothing to do with cartilage.
Benefits — Thymalin
- Reported immune restoration
Russian studies describe normalisation of lymphocyte subsets in immunodepressed patients.
- Long-term mortality signal
A multi-year cohort study reported reduced mortality in treated elderly subjects. The study design and independence are significant caveats.
- Long clinical use history
Decades of use in Russian practice without prominent safety signals reported.
Risks & cons — Cartalax
- No human data of any kind
Nothing has been measured in a person: no absorption study, no tolerability study, no efficacy trial, no imaging of a joint. A registry search returns no study of this compound under any of its names. Everything claimed for it in people is extrapolation from cultured cells.
- Unapproved grey-market material of unverifiable identity
It is not an approved medicine anywhere, and the injectable powder circulates under research-use-only labelling with no oversight of identity, purity, sterility or endotoxin. A three-residue peptide is cheap to fake and impossible to tell apart from filler by eye.
- The entire evidence base comes from one research group
Almost every paper on this sequence lists the same St Petersburg institute, and the one study run in a laboratory outside Russia carries the same two Russian authors. No independent group has reproduced any of it, which is a different and weaker position than simply being untested.
- Delaying real osteoarthritis care
Osteoarthritis has treatments with actual trial evidence behind them, including exercise therapy, weight management, established analgesia and, at the end of the road, joint replacement. Substituting an untested peptide for assessment of a painful joint is the practical harm most likely to occur here.
- Gene-expression effects are not benign by default
The reported actions include raising IGF1, NF-kappa-B and a tankyrase gene tied to telomere maintenance, and altering sirtuins and p53. Those are growth, inflammation and senescence pathways. Nobody has looked at what sustained exposure does, and the oncologic question has not been asked at all.
Risks & cons — Thymalin
- Undefined composition
An extract rather than a defined molecule, so batch consistency and mechanism attribution are both uncertain.
- No independent replication
The evidence base traces almost entirely to one research tradition and has not been reproduced elsewhere.
- Bovine biological source
Theoretical transmissible agent concerns and hypersensitivity risk from animal-derived protein.
- Autoimmune and transplant contraindications
Immune stimulation is inappropriate in autoimmune disease and after transplant.
- Unregulated in the West
Imported product has no quality assurance.
A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.